Stock Price Forecast
The 6 analysts offering 12-month price forecasts for Amyris Inc have a median target of 12.50, with a high estimate of 22.00 and a low estimate of 8.00. The median estimate represents a +175.94% increase from the last price of 4.53.
Similarly Should I buy AMRS stock now? Is Amyris a buy right now? 4 Wall Street equities research analysts have issued « buy, » « hold, » and « sell » ratings for Amyris in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should « buy » Amyris stock.
Why did Amyris drop? While the major catalyst for the stock’s decline is the company’s uninspiring third-quarter 2021 earnings report, shareholders are also likely hitting the sell button in response to the company’s capital raise as well as Wall Street’s unfavorable take on the stock.
Additionally, Who owns AMRS stock?
Top 10 Owners of Amyris Inc
| Stockholder | Stake | Total change |
|---|---|---|
| The Vanguard Group, Inc. | 5.35% | -2.42% |
| Farallon Capital Management LLC | 5.25% | +53.69% |
| BlackRock Fund Advisors | 3.40% | -11.54% |
| BlackRock Advisors LLC | 2.93% | -12.22% |
Is AMRS undervalued?
Amyris (NASDAQ:AMRS) is undervalued given its current growth potential. The product pipeline works and will create disruptions in many ingredient segments.
When did Amyris go public? Amyris is registered under the ticker NASDAQ:AMRS . Their stock opened with $16.00 in its Sep 28, 2010 IPO.
What kind of company is AMRS? Amyris, Inc. is a synthetic biotechnology company.
Is Zymergen publicly traded? Zymergen Inc is a chemicals business based in the US. Zymergen shares (ZY) are listed on the NASDAQ and all prices are listed in US Dollars.
Is Ginkgo Bioworks publicly traded?
Ginkgo Bioworks — a Boston-based company that wants to make biology as easy to program as a computer — began trading on Friday after going public via a SPAC. Why it matters: Ginkgo’s multibillion-dollar offering is a milestone in the maturation of synthetic biology from a science to a true industry.
Why did AMRS stock drop? Failing to meet analysts’ top-line estimates, Amyris reported a 30% year-over-year decline in its ingredients business, to the chagrin of investors, and it seems as if the company will continue to face challenges in the fourth quarter.
Who owns Amyris Inc?
Amyris (company)
| Type | Public |
|---|---|
| Founded | 2003 |
| Headquarters | Emeryville, California, USA |
| Key people | John G. Melo (CEO) Eduardo Alvarez (COO) Han Kieftenbeld (CFO) Nicole Kelsey (Gen.Counsel & Secretary) |
| Brands | Biossance, Pipette, Purecane, Costa Brazil, EcoFabulous, Rose Inc, Terasana, JVN and OLIKA. |
Is Amrs overvalued? PB vs Industry: AMRS is overvalued based on its PB Ratio (5.8x) compared to the US Chemicals industry average (2.3x).
Is Amyris overvalued?
The stock of Amyris (NAS:AMRS, 30-year Financials) is estimated to be significantly overvalued, according to GuruFocus Value calculation.
Who is Biossance owned by?
On March 1, Amyris, which owns Biossance and children’s skin-care brand Pipette, announced it acquired clean luxury beauty brand Costa Brazil for an undisclosed sum and that founder Francisco Costa will become the chief creative officer of the parent company.
What company owns Biossance? Amyris was founded in 2003. The company owns three brands, Biossance and Pipette, for beauty and skincare, and Purecane, a sugar substitute.
Who owns Amyris Inc? General Public Ownership
A substantial ownership of 40.97% in AMRS is held by the general public. This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses.
Should I invest in Zymergen?
Valuation metrics show that Zymergen Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ZY, demonstrate its potential to underperform the market.
Is Zymergen a good buy? Is Zymergen Stock a good buy in 2022, according to Wall Street analysts? The consensus among 7 Wall Street analysts covering (NASDAQ: ZY) stock is to Sell ZY stock.
Is Zymergen a good stock to buy?
Zymergen has received a consensus rating of Hold. The company’s average rating score is 1.63, and is based on no buy ratings, 5 hold ratings, and 3 sell ratings.
Does Bill Gates own Ginkgo Bioworks? 1. Ginkgo Bioworks. Ginkgo Bioworks is a biotech company that went public through a special purpose acquisition company last year. The company has the backing of Bill Gates and can design and print DNA.
Who invested in ginkgo?
Ginkgo’s proceeds come from a private placement of $775 million from investors — led by Baillie Gifford, Putnam Investments, and Morgan Stanley — and about $858 million from the Soaring Eagle trust account.
Is Ginkgo Bioworks profitable? So why would an investor consider Ginkgo Bioworks a story stock? Well, the company hasn’t brought in much actual revenue yet. While there are about 61 active cell programs as of Q3 2021 earnings, the company’s done $79 million in revenue through the first three quarters of 2021.
